Flputnam Investment Management Co. Makes New Investment in Genelux Corporation $GNLX

Posted by Brenda Bartman on Aug 18th, 2026

Flputnam Investment Management Co. acquired a new stake in Genelux Corporation (NASDAQ:GNLX – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 231,405 shares of the company’s stock, valued at approximately $697,000. Flputnam Investment Management Co. owned approximately 0.52% of Genelux as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in GNLX. GSA Capital Partners LLP purchased a new position in shares of Genelux in the second quarter valued at $35,000. Jefferies Financial Group Inc. acquired a new stake in Genelux during the 4th quarter valued at $48,000. Squarepoint Ops LLC purchased a new stake in Genelux during the 4th quarter worth $52,000. Raymond James Financial Inc. increased its stake in Genelux by 22.6% during the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after buying an additional 5,333 shares during the period. Finally, Marshall Wace LLP acquired a new position in Genelux in the 2nd quarter worth $92,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GNLX. Wall Street Zen cut shares of Genelux from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Genelux currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Read Our Latest Research Report on GNLX

Insider Transactions at Genelux

In related news, Director John W. Smither sold 12,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total value of $34,920.00. Following the completion of the sale, the director directly owned 91,403 shares of the company’s stock, valued at $265,982.73. The trade was a 11.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director John Thomas sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $2.98, for a total value of $29,800.00. Following the sale, the director owned 472,784 shares in the company, valued at $1,408,896.32. The trade was a 2.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,868 shares of company stock valued at $76,120 over the last quarter. Insiders own 7.50% of the company’s stock.

Genelux Trading Down 1.5%

Shares of NASDAQ:GNLX opened at $2.70 on Tuesday. The firm has a market cap of $121.07 million, a PE ratio of -3.14 and a beta of 0.60. The company has a fifty day simple moving average of $2.89 and a 200 day simple moving average of $2.77. Genelux Corporation has a 12-month low of $2.29 and a 12-month high of $8.53.

Genelux (NASDAQ:GNLX – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). As a group, equities research analysts forecast that Genelux Corporation will post -0.8 EPS for the current fiscal year.

About Genelux

(Free Report)

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.